August 15, 2022

Healty Care

The Healthy Lovers

Chesley Taft & Associates LLC Has $40.97 Million Stock

4 min read

Chesley Taft & Associates LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 227,718 shares of the company’s stock after selling 6,503 shares during the quarter. Johnson & Johnson accounts for about 2.4% of Chesley Taft & Associates LLC’s holdings, making the stock its 7th biggest holding. Chesley Taft & Associates LLC’s holdings in Johnson & Johnson were worth $40,966,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in JNJ. Family CFO Inc purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $34,000. Advocacy Wealth Management Services LLC raised its stake in shares of Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after acquiring an additional 67 shares in the last quarter. Iron Horse Wealth Management LLC raised its stake in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 68.78% of the company’s stock.

In related news, insider William Hait sold 29,699 shares of the company’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,161 shares of company stock worth $13,895,302. Company insiders own 0.35% of the company’s stock.

NYSE:JNJ opened at $176.94 on Wednesday. The stock has a market cap of $465.60 billion, a P/E ratio of 23.85, a price-to-earnings-growth ratio of 3.61 and a beta of 0.66. The firm’s fifty day simple moving average is $177.67 and its 200 day simple moving average is $173.59. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. During the same quarter in the previous year, the business posted $2.59 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date of this dividend was Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is 60.92%.

Several research analysts have commented on the stock. Raymond James lifted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Citigroup decreased their target price on shares of Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $190.50.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.